{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:55:23Z","timestamp":1790117723948,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>With increasing life expectancy, the number of older patients with metastatic castration-resistant prostate cancer (mCRPC) continues to rise, but this group is currently underrepresented in clinical trials. This study aims to assess the efficacy and safety of prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) in patients over 85 years old with mCRPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A retrospective analysis was conducted on 21 mCRPC patients aged 85 years or older receiving PSMA-RLT (range: 85\u201396\u00a0y). The median number of treatment cycles was 4 (range: 1\u201313 cycles), with a mean cumulative administered activity of 26.9\u00b117.3\u00a0GBq (range: 8.0\u201387.2\u00a0 GBq) of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617. Adverse events, including anemia, thrombocytopenia, leukopenia, renal impairment, fatigue, and xerostomia were classified according to CTCAE version 5.0.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean best PSA response across the cohort was \u201337.6\u00b173.3%, with 62% (13 of 21 patients) showing partial remission. Median progression-free survival and overall survival were 4.6 and 14.7 months, respectively. Severe adverse events were rare, occurring in 2 patients: 1 case of grade 3 anemia and 1 of grade 3 thrombocytopenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The results demonstrate that PSMA-RLT is an effective and well-tolerated treatment for mCRPC patients over 85 years, with clinical outcomes and safety comparable to those observed in studies involving younger populations. This highlights its potential as a valuable therapeutic option for this aging patient group.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005968","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T10:01:54Z","timestamp":1747130514000},"page":"825-829","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["PSMA Radioligand Therapy in Advanced Age"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2106-9548","authenticated-orcid":false,"given":"Moritz B.","family":"Bastian","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"W\u00f6rl","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-8860","authenticated-orcid":false,"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Speicher","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0273-2183","authenticated-orcid":false,"given":"Joel","family":"Wessendorf","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-5786","authenticated-orcid":false,"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-4099","authenticated-orcid":false,"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, Homburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s12094-015-1480-y","article-title":"Role of taxanes in advanced prostate cancer","volume":"18","author":"Cassinello","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/RLU.0000000000005253","article-title":"225 Ac-PSMA-617 augmentation in high-risk mCRPC undergoing 177 Lu-PSMA-617 radioligand therapy: pilot experience from a prospective registry","volume":"49","author":"Rosar","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.7150\/thno.56211","article-title":"Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617\/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy","volume":"11","author":"Rosar","year":"2021","journal-title":"Theranostics"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"R14-20250731","first-page":"241969","article-title":"Radioligand treatment with [177Lu]Lu-PSMA I&T in the older patients\u2014safety, efficacy, and prognostic factors for survival","volume":"65","author":"Weber","year":"2024","journal-title":"J Nucl Med"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2174\/0118744710284661240328094119","article-title":"177Lu-PSMA-617 radioligand treatment in elderly patients with metastatic castration-resistant prostate cancer: therapeutic efficacy and safety assessment","volume":"17","author":"Sahin","year":"2024","journal-title":"Curr Radiopharm"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","article-title":"Safety and efficacy of [177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years","volume":"64","author":"Tauber","year":"2023","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/jpm13020319","article-title":"Analysis of frailty syndrome in men with metastatic prostate cancer: a scoping review","volume":"13","author":"Mafla-Espa\u00f1a","year":"2023","journal-title":"J Pers Med"},{"key":"R18-20250731","first-page":"362","article-title":"Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/epirev\/mxs009","article-title":"Multimorbidity in older adults","volume":"35","author":"Salive","year":"2013","journal-title":"Epidemiol Rev"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-024-00346-4","article-title":"Ageing-related bone and immunity changes: insights into the complex interplay between the skeleton and the immune system","volume":"12","author":"Mi","year":"2024","journal-title":"Bone Res"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1007\/s00259-023-06139-x","article-title":"Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020","volume":"50","author":"Flegar","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:35Z","timestamp":1753938035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005968"}},"subtitle":["Insights From an 85y+ mCRPC Patient Cohort"],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005968","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"2025-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}